Cargando…
External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
BACKGROUND: Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparativ...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434413/ https://www.ncbi.nlm.nih.gov/pubmed/35930972 http://dx.doi.org/10.1016/j.esmoop.2022.100551 |
_version_ | 1784780868758274048 |
---|---|
author | Rolfo, C. Hess, L.M. Jen, M.-H. Peterson, P. Li, X. Liu, H. Lai, Y. Sugihara, T. Kiiskinen, U. Vickers, A. Summers, Y. |
author_facet | Rolfo, C. Hess, L.M. Jen, M.-H. Peterson, P. Li, X. Liu, H. Lai, Y. Sugihara, T. Kiiskinen, U. Vickers, A. Summers, Y. |
author_sort | Rolfo, C. |
collection | PubMed |
description | BACKGROUND: Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparative efficacy [objective response rate (ORR), progression-free survival, and overall survival (OS)] in first- and second-line treatment settings. METHODS: Patient-level data were obtained from a de-identified real-world database. Patients diagnosed with advanced/metastatic NSCLC with no prior exposure to a RET inhibitor and one or more prior line of therapy were eligible. Additionally, individual patient-level data (IPD) were obtained from the pemetrexed + platinum arm of KEYNOTE-189 (NCT03950674, first line) and the docetaxel arm of REVEL (NCT01168973, post-progression). Patients were matched using entropy balancing, doubly robust method, and propensity score approaches. For patients with unknown/negative RET status, adjustment was made using a model fitted to IPD from a real-world database. RESULTS: In first-line unadjusted analyses of the real-world control, ORR was 87.2% for LIBRETTO-001 versus 66.7% for those with RET-positive NSCLC (P = 0.06). After adjustment for unknown RET status and other patient characteristics, selpercatinib remained significantly superior versus the real-world control for all outcomes (all P < 0.001 except unadjusted RET-fusion-positive cohort). Similarly, outcomes were significantly improved versus clinical trial controls (all P < 0.05). CONCLUSIONS: Findings suggest improvement in outcomes associated with selpercatinib treatment versus the multiple external control cohorts, but should be interpreted with caution. Data were limited by the rarity of RET, lack of mature OS data, and uncertainty from assumptions to create control arms from external data. |
format | Online Article Text |
id | pubmed-9434413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94344132022-09-02 External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer Rolfo, C. Hess, L.M. Jen, M.-H. Peterson, P. Li, X. Liu, H. Lai, Y. Sugihara, T. Kiiskinen, U. Vickers, A. Summers, Y. ESMO Open Original Research BACKGROUND: Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparative efficacy [objective response rate (ORR), progression-free survival, and overall survival (OS)] in first- and second-line treatment settings. METHODS: Patient-level data were obtained from a de-identified real-world database. Patients diagnosed with advanced/metastatic NSCLC with no prior exposure to a RET inhibitor and one or more prior line of therapy were eligible. Additionally, individual patient-level data (IPD) were obtained from the pemetrexed + platinum arm of KEYNOTE-189 (NCT03950674, first line) and the docetaxel arm of REVEL (NCT01168973, post-progression). Patients were matched using entropy balancing, doubly robust method, and propensity score approaches. For patients with unknown/negative RET status, adjustment was made using a model fitted to IPD from a real-world database. RESULTS: In first-line unadjusted analyses of the real-world control, ORR was 87.2% for LIBRETTO-001 versus 66.7% for those with RET-positive NSCLC (P = 0.06). After adjustment for unknown RET status and other patient characteristics, selpercatinib remained significantly superior versus the real-world control for all outcomes (all P < 0.001 except unadjusted RET-fusion-positive cohort). Similarly, outcomes were significantly improved versus clinical trial controls (all P < 0.05). CONCLUSIONS: Findings suggest improvement in outcomes associated with selpercatinib treatment versus the multiple external control cohorts, but should be interpreted with caution. Data were limited by the rarity of RET, lack of mature OS data, and uncertainty from assumptions to create control arms from external data. Elsevier 2022-08-02 /pmc/articles/PMC9434413/ /pubmed/35930972 http://dx.doi.org/10.1016/j.esmoop.2022.100551 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Rolfo, C. Hess, L.M. Jen, M.-H. Peterson, P. Li, X. Liu, H. Lai, Y. Sugihara, T. Kiiskinen, U. Vickers, A. Summers, Y. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer |
title | External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer |
title_full | External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer |
title_fullStr | External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer |
title_full_unstemmed | External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer |
title_short | External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer |
title_sort | external control cohorts for the single-arm libretto-001 trial of selpercatinib in ret+ non-small-cell lung cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434413/ https://www.ncbi.nlm.nih.gov/pubmed/35930972 http://dx.doi.org/10.1016/j.esmoop.2022.100551 |
work_keys_str_mv | AT rolfoc externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT hesslm externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT jenmh externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT petersonp externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT lix externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT liuh externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT laiy externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT sugiharat externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT kiiskinenu externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT vickersa externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer AT summersy externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer |